New US Compassionate Use Tool Would Need Support Of Drug Makers
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration and not-for-profit organization, the Reagan-Udall Foundation, are exploring a proposed tool that could make it easier for physicians and patients seeking access to unapproved drugs by providing a central repository of information about biopharma manufacturers' policies and points of contact1,2.
You may also be interested in...
NIH Funding Component of 21st Century Cures May Get White House Boost
Vice President’s Cancer Moonshot project could provide final thrust for '21st Century Cures' bill in the lame duck Congressional session after election.
'Right To Try' Or 'Right To Ask'? Hearing Spotlights Adverse Events As Key Barrier To Expanded Access
FDA and the pharmaceutical industry appear to have a shared interest in finding ways to dramatically increase expanded access programs to avoid a potentially difficult fight over 'Right to Try' legislation at the federal level in 2017. A September 22 hearing on a pending Senate bill illustrates why.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.